AbbVie Inc. $ABBV Shares Sold by BLB&B Advisors LLC

Key Points

• BLB&B Advisors LLC reduced its AbbVie stake by 5.2% in the third quarter, selling 4,186 shares and retaining 76,638 shares valued at approximately $20.05 million. Institutional investors collectively own 70.23% of ABBV.
• Analysts maintain a generally positive outlook, with AbbVie holding a consensus “Moderate Buy” rating and an average price target of $279.86. However, concerns remain about the stock’s elevated valuation, rising expenses, competition and the longer-term impact of Humira’s decline.
• AbbVie reported quarterly revenue of $16.99 billion and EPS of $3.65, exceeding estimates, while highlighting growth from Skyrizi, Rinvoq and its oncology pipeline. The company also declared a quarterly dividend of $1.73, equivalent to a $6.92 annualized payout and a 2.4% yield.

BLB&B Advisors LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,638 shares of the company's stock after selling 4,186 shares during the period. BLB&B Advisors LLC's holdings in AbbVie were worth $20,048,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ABBV. AMI Investment Management Inc. acquired a new position in AbbVie during the third quarter valued at $245,000. Sigma Investment Counselors Inc. increased its holdings in shares of AbbVie by 10.6% in the 3rd quarter. Sigma Investment Counselors Inc. now owns 34,537 shares of the company's stock valued at $9,034,000 after purchasing an additional 3,299 shares during the period. Victory Financial Group LLC lifted its position in shares of AbbVie by 31.2% in the third quarter. Victory Financial Group LLC now owns 11,631 shares of the company's stock worth $3,042,000 after purchasing an additional 2,768 shares in the last quarter. Guerra Pan Advisors LLC lifted its position in shares of AbbVie by 2.1% in the third quarter. Guerra Pan Advisors LLC now owns 3,100 shares of the company's stock worth $876,000 after purchasing an additional 65 shares in the last quarter. Finally, Willow Creek Wealth Management Inc. boosted its holdings in shares of AbbVie by 3.7% during the third quarter. Willow Creek Wealth Management Inc. now owns 1,480 shares of the company's stock worth $387,000 after purchasing an additional 53 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
• Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
• Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
• Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
• Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $280.00 price objective on shares of AbbVie in a research note on Tuesday, October 13th. Piper Sandler upped their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Oppenheimer increased their price objective on AbbVie from $244.00 to $258.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Barclays lifted their price objective on AbbVie from $300.00 to $325.00 and gave the company an "overweight" rating in a research report on Wednesday, October 21st. Finally, HSBC lifted their price target on AbbVie from $300.00 to $315.00 and gave the company a "buy" rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and a consensus target price of $279.86.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

AbbVie Stock Performance

Shares of ABBV opened at $286.10 on Thursday. The company has a market cap of $505.47 billion, a price-to-earnings ratio of 80.82, a PEG ratio of 1.30 and a beta of 0.24. The stock has a fifty day moving average price of $268.20 and a two-hundred day moving average price of $236.51. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the previous year, the business posted $2.97 earnings per share. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's payout ratio is 195.48%.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.